Evidence in support of probucol, an antioxidant, being the drug of choice in the treatment of atherosclerotic vascular disease
Embargo Date
Indefinite
OA Version
Citation
Abstract
Atherosclerotic vascular disease (AVO) is a major contributing factor to our nation's leading cause of death, cardiovascular disease. Several mechanisms have been proposed in the genesis of AVO, one of the most persuasive being that the oxidized low density lipoprotein (LDL), not the native LDL, is the form recognized and taken up by intimal macrophages leading to the development of cholesterol-rich foam cells of atheranatous plaques. Probucol, an antioxidant, blocks the conversion of LDL to oxidized Probucol, an antioxidant, blocks the conversion LDL and slows the atherosclerotic process. After reviewing other mechanisms and treatments in AVO, the evidence , in my opinion, favors probucol as being the drug of choice in AVO managerrent.
Description
Thesis (M.A.)--Boston University
License
PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you.